论文部分内容阅读
In the early phase development of molecularly targeted agents(MTAs),a commonly encountered situation is that the MTA is expected to be more effective for a certain biomarker subgroup,say marker-positive patients,but there is no adequate evidence to show that the MTA does not work for the other subgroup,i.e.,marker-negative patients.